Navigation Links
Depo-Provera Birth Control Might Raise Breast Cancer Risk
Date:4/4/2012

WEDNESDAY, April 4 (HealthDay News) -- There appears to be a link between an injectable form of progestin-only birth control, best known as Depo-Provera, and an increased risk of breast cancer in young women, new research suggests.

For the study, researchers compared more than 1,000 Seattle-area women, aged 20 to 44, who were diagnosed with breast cancer, and more than 900 women without breast cancer.

Recent use of the injectable contraceptive (formally called depo-medroxyprogesterone acetate or DMPA) for a year or longer was associated with a 2.2-fold increased risk of invasive breast cancer, the study found.

This increased risk appeared to fade within months after women stopped using the contraceptive, and women who used the contraceptive for less than a year or who had stopped using it more than a year earlier did not have any increased risk of breast cancer, according to the findings published online and in the April 15 print issue of the journal Cancer Research.

"Although breast cancer is rare among young women and the elevated risk of breast cancer associated with DMPA appears to dissipate after discontinuation of use, our findings emphasize the importance of identifying the potential risks associated with specific forms of contraceptives given the number of available alternatives," study leader Dr. Christopher Li, a breast cancer epidemiologist at the Fred Hutchinson Cancer Research Center in Seattle, and colleagues wrote.

"In the United States, many women have numerous options for contraception, and so it is important to balance their risks and benefits when making contraceptive choices," Li noted in a news release from the research center.

While the study uncovered an association between Depo-Provera and raised breast cancer risk, it could not prove a cause-and-effect relationship.

Commenting on the study, Dr. Elizabeth Poynor, a gynecologic oncologist and pelvic surgeon at Lenox Hill Hospital in New York City, said, "This study further confirms that some types of progestins are not healthy for the breast. For women who are at elevated risk to develop breast cancer based on family history, or even age, this type of contraception may not be a good choice for them."

But another expert cautioned that the study did have its limits.

Dr. Freya Schnabel, director of breast surgery at NYU Clinical Cancer Center in New York City, noted that the women in the study who seemed at highest risk of developing breast cancer while on Depo-Provera were those with a family history of the disease or women who had never had children (another known risk factor).

Furthermore, she said, "the study did not include information about all breast cancer risk factors in the participants, and this is a real limitation of the analysis which could impact on the results. Also, the mechanism by which the progesterone would increase risk only in current users is not clear."

According to Schnabel, all of this means that "more detailed studies are needed to clarify the relationship between this contraceptive method and risk of breast cancer."

The research was funded by the U.S. National Cancer Institute and the Department of Defense Breast Cancer Research Program.

More information

Planned Parenthood has more about the birth control shot.

-- Robert Preidt

SOURCES: Elizabeth Poynor, M.D., Ph.D., Lenox Hill Hospital, New York City; Freya Schnabel, M.D., director of breast surgery, NYU Clinical Cancer Center, New York City; Fred Hutchinson Cancer Research Center, news release, April 4, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Giving Birth to Small Babies Linked to Heart Disease in Moms: Study
2. Late Preemie Birth May Be Linked to Higher Asthma Risk
3. Timing of Preemie Birth May Be Key to Kids Health Later
4. Another Batch of Birth Control Pills Recalled for Faulty Packaging
5. Women with rheumatoid arthritis and lupus give birth to fewer children
6. Weekend Delivery Doesnt Hurt Babies With Birth Defects: Study
7. Study weighs risks and benefits of birthing facilities
8. Risk of Preterm Birth Rises for Hispanic Women the Longer Theyre in U.S.
9. Study finds residence in US a risk factor for preterm birth
10. Pfizer Recalls 1 Million Packets of Birth Control Pills
11. When Mom-to-Bes Overweight and Smokes, Risk for Birth Defects Rises
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Depo-Provera Birth Control Might Raise Breast Cancer Risk
(Date:9/21/2017)... Falls Church, VA (PRWEB) , ... September 21, ... ... Use Policy , **An FDAnews Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the ... every edge they can get while staying in compliance with FDA rules. , ...
(Date:9/21/2017)... WA (PRWEB) , ... September 21, 2017 , ... ... technology using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 in ... of the life-sciences industry for ensuring label quality and improving patient safety. ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand that ... detail to the athletic wear market with the launch of their FlipBelt Crops. , ... their essentials securely at their fingertips while at the gym, on the trail, or ...
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ( http://www.firstalign.com ), combines ... Artificial Intelligence (AI) thinking, announced today the launch of its revamped web presence. ... information that offers a more comprehensive understanding of the organization’s business and machine ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... and commercialization, has just released a new white paper discussing the benefits ... than ever about medical device, pharmaceutical, and combination product organizations making sure ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a ... it will host an educational session focused on the ... infection (CLABSI) prevention at the 2017 Annual Scientific Meeting ... will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
Breaking Medicine Technology: